Skip to main content
OpenTrials
Completed

NCT Number: NCT04101370

Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer® 125 mg Tablets IR In Healthy Subjects

Bioequivalence Study of 2 formulation of bosentan (Bosentan GEROPHARM vers. Tracleer® Actelion)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Clinical Hospital № 3

Yaroslavl, 150007, Russia

About this study

Study to evaluate the bioequivalence of orally administered bosentan preparations, immediate release tablets, 125 mg in normal healthy subjects under fasting conditions

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent form.
  • Healthy male aged 18 to 45 years.
  • Verified diagnosis is "healthy" according to data Standard clinical, laboratory and Instrumental methods of examination.
  • Have a body mass index between 18,5 and 30 kg/m2.
  • Subjects must use, with their partner, methods of highly effective contraception throughout the study and 30 days after the end of study.
  • Ability to keep fasting state for at least 14 hours.
  • Consent and ability to respect the schedule of visits and the points of the Protocol.

Exclusion criteria

  • History of serious allergic problems/events.
  • Medicinal intolerance.
  • Any acute and chronic diseases of the cardiovascular system, cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.
  • Psychiatric disorders, history of epilepsy and seizures.
  • Acute infectious diseases in less than 4 weeks before the start of the study.
  • Subjects who have taken medication 2 weeks preceding before the study.
  • Subjects who have taken any drugs known effects on hemodynamics or to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication (examples of inducers: barbiturates, omeprazole, etc.).
  • Donation of plasma (450 mL or more) within 2 month prior to administration of the study medication.
  • History of significant alcohol or drugs abuse or any indication of the regular use of more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or 50 mL of alcohol 40%).
  • Smokers.
  • Participation in other clinical training is less than than for 3 months before the study.
  • Lack of signed informed consent form.
  • 10% deviation from references in lab tests.
  • Positive testing for alcohol, drugs.
  • Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours before the start of the study.
  • Any diet (vegetarian, etc.) extreme physical exercise, night shift work.
  • Heart rate below 60 or above 80 beats per minute.
  • Systolic blood pressure less than 110 mm Hg or more than 139 mm Hg.
  • Diastolic blood pressure less than 60 mm Hg or more than 89 mm Hg.
  • Volunteers, for Investigator opinion, who can not understand and evaluate the information about this study.

Treatment and study plan

Bosentan 125 mg

Drug

Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition

Other names: bosentan

Tracleer 125Mg Tablet

Drug

Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition

Other names: bosentan

Primary outcomes

  1. Cmax

    Time frame: 0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.

    Pharmacokinetics of bosentan by Assessment of Observed Maximum Plasma Concentration (Cmax)

  2. AUC(0-t)

    Time frame: 0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.

    Pharmacokinetics of bosentan by Assessment of Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t))

Sponsors and collaborators

Lead sponsor

Geropharm

Industry

Registry information

Official study title

Two-way Crossover, Open-label, Single-dose, Bioequivalence Study of Bosentan (LLC "GEROPHARM", Russia) 125 mg Tablets Immediate Release (IR )Versus Tracleer® (Actelion Pharmaceuticals Ltd., Switzerland) 125 mg Tablets IR in Normal Healthy Subjects Under Fasting Conditions

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Sep 24, 2019
Registry last updated
Sep 24, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.